Feasibility Report and Action Plan
Detailed Tender Analysis (ID: 623185-2025)
To assess the viability of our participation and build a winning offer, it is imperative to fully understand the details of the tender. This section breaks down the critical components, extracting key information directly from the official documentation.
The following is a summary table with the most relevant data from the procedure:
| Element | Description |
|---|---|
| Procedure Title | Bereitstellung und Betrieb einer digitalen Plattform zur teledermatologischen Konsultation (Provision and operation of a digital platform for teledermatological consultation). |
| Publication Number (TED) | 623185-2025 |
| Internal Procedure ID | 9e12c4d9-cd1b-4d90-adbd-c778aa2f3511 |
| Contracting Authority (Beschaffer) | AOK Sachsen-Anhalt |
| Object of the Contract | Implementation of a care model for insured persons with skin diseases. The contractor must provide and operate a digital platform, making the services available through participating health providers (durch teilnehmende Leistungserbringer). |
| Single Lot (LOT-0001) | Provision and operation of a digital platform for teledermatological consultation. |
| Contract Type | Services (Dienstleistungen) |
| Relevant CPV Codes | 72000000 - IT services 85100000 - Health services 85150000 - Medical imaging services |
Award Criteria
The evaluation system decisively favors technical excellence. The score is distributed with 30% for price and 70% for quality. The quality assessment will be based on the "bidder's proposals to the requirements of Form B-Criteria" and the "coherence of the concept" presented. This means that a detailed proposal, demonstrating a deep understanding of the client's needs and a superior technological solution, will be decisive.
Critical Deadlines
The tender schedule presents a significant challenge. Assuming the current date is October 18, 2025, the deadlines are as follows:
- Deadline for Request for Additional Information: The deadline was October 15, 2025. This date has already passed, which prevents us from requesting clarifications on the specifications.
- Deadline for Submission of Bids: The deadline for submission is October 24, 2025, at 10:00:00 (UTC+2).
- Analysis of Remaining Time: We have only 6 days to prepare, translate, and submit a complete, high-quality proposal. This deadline is extremely tight and must be considered a critical risk for the project, requiring immediate mobilization and flawless execution.
This analysis of the requirements and deadlines forces us to quickly assess whether Legit.Health's capabilities align with what is requested and whether we can act with the speed that the situation demands.
Evaluation of Legit.Health's Suitability
The purpose of this section is to demonstrate the robust and direct alignment between the capabilities of the Legit.Health Plus product and the explicit requirements of LOT-0001 of the tender. Our platform not only meets but exceeds the expectations for a modern and effective teledermatology solution.
Legit.Health is technically suitable for LOT-0001 due to its nature as a computational medical software device designed specifically for processing skin images. The platform serves a dual function: on one hand, it quantifies clinical signs (such as erythema or scaling), and on the other, it provides a distributive and interpretive representation of possible ICD (International Classification of Diseases) categories that may be represented in the image. This dual approach positions Legit.Health as an advanced clinical decision support tool for healthcare professionals, aligning perfectly with the tender's objective of facilitating specialized, rapid, and remote evaluation.
The following table details the fit between the tender requirements and the specific capabilities of our platform:
| Tender Requirement | Legit.Health Capability |
|---|---|
| Digital Platform | Medical Device Software (MDSW) platform with a REST API architecture for flexible integration into client systems. |
| Teledermatology Consultation | Processing of skin images with computer vision algorithms to assist in clinical evaluations and monitoring of pathologies. |
| Health Services (CPV 85100000) | Classified as a medical device (Class IIb according to MDR 2017/745) with the explicit purpose of diagnosis, monitoring, and alleviation of skin diseases. |
| Interoperability (Implicit) | Native support for the HL7 FHIR health data exchange standard, ensuring compatibility with existing systems such as electronic medical records (EMR). |
The strong technical and regulatory compatibility of Legit.Health with the tender requirements is evident. Now, it is crucial to address the risks and non-technical requirements to outline a complete proposal strategy.
Addressing Key Requirements and Risks
Despite the excellent technical fit of our solution, there are significant non-technical risks that must be proactively managed to ensure the viability of the proposal. This section focuses on the strategy to mitigate the main perceived obstacle—the provision of medical services—and other critical operational risks.
The "400 Dermatologists" Requirement: Analysis and Mitigation Strategy
An internal concern has been raised about an alleged requirement to have "400 dermatologists nationwide already on board." After a thorough review of the provided tender excerpts, this specific numerical requirement is not documented. The specifications refer generally to the need for the contractor to make the services available "through participating health providers" (teilnehmende Leistungserbringer).
However, to proactively address any such requirement, we propose a strategy based on subcontracting. The specifications explicitly allow for this ("Die Einschaltung von Nachunternehmern für einzelne Teilleistungen ist jeweils möglich"). Our strategy will be to position Legit.Health as the main technological provider of the digital platform, while we partner with a local German entity (a network of clinics, a medical society, etc.) to act as a subcontractor to provide the network of medical professionals (Leistungserbringer). This strategy not only mitigates the risk but also strengthens our proposal by incorporating local knowledge and networks, a factor that AOK will value positively in the evaluation of the "coherence of the concept."
Operational Risks: Language and Submission Deadline
- Language: The tender documentation is clear: bids must be submitted in German ("Deutsch"). This requirement is non-negotiable and requires the immediate hiring of professional and sworn translation services to ensure the highest quality, precision, and terminological adequacy of our proposal.
- Deadline: It is reiterated that the 6-day deadline is the most critical risk of the project. It demands a total and immediate mobilization of the assigned resources, agile decision-making by the management team, and perfect coordination among all involved departments (Technical, Commercial, and Legal).
The analysis of these risks leads us directly to the formulation of an immediate and rigorous action plan.
Immediate Action Plan (Oct 18 - Oct 24)
Given the urgency and the extremely short deadline, flawless and coordinated execution is essential. The following plan details the critical actions, key responsible parties, and deadlines to develop and submit a competitive proposal by October 24.
| Phase / Task | Key Responsible(s) | Deadline |
|---|---|---|
| Phase 1: Decision and Mobilization | Management Team | Oct 18 |
| 1.1. Final Go/No-Go decision. | ||
| 1.2. Assignment of a dedicated work team (Technical, Commercial, Legal). | ||
| 1.3. Hiring of sworn translation services into German. | ||
| Phase 2: Strategy and Alliances | Business Development | Oct 20 |
| 2.1. Urgent identification and contact with potential German partners (clinics, dermatologist networks) for the subcontractor role. | ||
| Phase 3: Proposal Preparation | Work Team | Oct 23 |
| 3.1. Drafting of the Quality section (70%), highlighting key differentiators. | Technical Lead | |
| 3.2. Development of the competitive pricing strategy. | Commercial Lead | |
| 3.3. Compilation of all required administrative documentation. | Legal Team | |
| 3.4. Complete translation of the proposal into German. | External Translator / Team | |
| Phase 4: Review and Submission | Management Team | Oct 24 (10:00) |
| 4.1. Final review of the complete proposal in German. | ||
| 4.2. Electronic submission through the dtvp.de portal. |
Key Arguments for the Quality Proposal (70%)
To maximize our score in the quality criterion, the proposal must emphasize the following strengths, which are our key differentiators:
- Superior Technology: Our platform is based on an advanced Vision Transformer (ViT) architecture and a sophisticated model calibration process, which ensures superior accuracy and reliability in image analysis.
- Certification and Compliance: Legit.Health Plus is a certified Class IIb Medical Device under the strict European MDR 2017/745 regulation, which ensures the highest standards of safety and performance.
- Data Quality: We incorporate unique features such as DIQA (Dermatology Image Quality Assessment) and image domain verification to assess and ensure the quality of the images before processing, minimizing errors and improving the reliability of the results.
- Guaranteed Interoperability: Native support for the HL7 FHIR standard is crucial for a smooth and secure integration into the German healthcare ecosystem, including connection with existing EMR systems.
- Differential Clinical Output: Unlike tools that offer a binary diagnosis, our platform provides a probabilistic distribution of ICD categories. This approach positions our product as a more sophisticated and responsible clinical decision support tool, which enhances the physician's judgment rather than trying to replace it.
The correct articulation of these points will be fundamental to building a convincing narrative in our proposal.
Conclusion and Final Recommendation
This report has evaluated the AOK Sachsen-Anhalt tender, concluding that there is a strong technical alignment between the requirements of the specifications and the capabilities of the Legit.Health platform. The strategic opportunity that this contract represents is immense, and it could act as the main gateway to the competitive German healthcare market. However, critical risks have been identified that cannot be underestimated: the extremely short submission deadline, the requirement to submit the proposal in German, and the implicit need to have a network of medical service providers.
The final recommendation is to PROCEED with the submission of the bid, but this recommendation is strictly conditioned on the immediate and successful execution of the action plan detailed in the previous section. The success of this initiative depends, to a large extent, on our ability to quickly identify and secure a local German partner who can act as a subcontractor for the provision of medical services.
Despite the challenges, the strategic value of being awarded this tender justifies the intensive and concentrated effort required in the coming days. Winning this contract would not only represent a commercial success but also a transformative step for the positioning of Legit.Health in Europe.